<DOC>
	<DOCNO>NCT02713243</DOCNO>
	<brief_summary>The purpose study determine whether LJN452 improve symptom bile acid diarrhea ass safety tolerability profile patient primary bile acid diarrhea ( pBAD ) guide decision-making regard clinical development indication .</brief_summary>
	<brief_title>To Assess Safety , Tolerability Efficacy LJN452 Patients With Primary Bile Acid Diarrhea .</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Bile Acids Salts</mesh_term>
	<criteria>Key A history diarrheal symptom least 3 month prior dose Average stool frequency least 2 per day therapy AND Average stool form &gt; 5 Bristol Stool Chart . Previous laboratory radiological confirmation bile acid malabsorption either fecal bile acid loss OR 7 day 75Selenium homocholic acid taurine ( 75SeHCAT ) retention . Age â‰¥ 18 year . Key Patients diagnose lead diarrhea , include colorectal neoplasia , ulcerative colitis , Crohn 's disease , celiac disease , chronic pancreatitis , druginduced diarrhea active infection AND Patients investigated standard clinical assessment exclude disorder . Treatment bile acid sequestrants ( colestyramine , colestipol , colesevelam ) 2 week first dose LJN452 . A washout 14 day agent allow first dosing . Women childbearing potential , defined woman physiologically capable become pregnant . A positive Hepatitis B surface antigen Hepatitis C test result . History immunodeficiency disease , include positive HIV ( ELISA Western blot ) test result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Primary bile acid diarrhea ,</keyword>
	<keyword>FXR agonist ,</keyword>
	<keyword>bile acid malabsorption .</keyword>
</DOC>